Are there any for cognitive symptoms in phase 3?
And, any for positive or negative symptoms?
Are there any for cognitive symptoms in phase 3?
And, any for positive or negative symptoms?
Does anyone know whatever happened to the medication, LB?
This article was written in 2021 and it is 2024 but there are no new updates that are recent?
Amisulpride: What’s Old Can Be New in the United States | Psychiatric News (psychiatryonline.org)
@robertc keeps an eye on these things.
I mostly look at new drugs for positives. It seems like a new med gets approved only every 4 years or so and most bomb. Caplyta approved December 2019 comes to mind last. Primavanserin just failed for negatives.Roluperidone also looks dead.
KarXT is likely for this summer or so. Brilaroxazine maybe early 2026 looks likely. Ulotaront is in delay or limbo after high placebo effect in trials.
Matsblog dot net from a Japanese patient has a small list of new meds for negatives or cognition. The Japanese patient used to organize all this stuff but is limiting info in English due to lack of clicks.
Icelepertin is in phase 3 for cognition. I’m actually participating in the trial and suspect I’m on the drug. We should also be getting news about evenamide in chronic schizophrenia any day now.
That is good to know.
Has your cognition improved on the medication? How are you feeling overall on it?
Pretty good. I’m a little less anxious than I am normally. I’m a little sharper verbally. The effects are subtle but their there.
I presume they would measure the cognitives physically, like a battery of tests to evaluate whether the medicine works or not?
Or, they are going to rely on questions related to your subjective feeling about the medication?
Correct, I went through two rounds of testing before we started the med.
So, it will really depend upon how you do on those tests. Your subjective feeling will not count at all, I presume?
I’m not sure. The med is for cognition but they asked me plenty of questions about my well being and recorded the answers. Maybe they’re measuring negatives as a secondary endpoint. Again, I’m not exactly sure.
So that means they will retry/ try I send them a message say what happend to your medication did it fail but I got no reply
They are still spending money on clinical trials. They have not yet announced discontinuation of their efforts.
What is a typical placebo effect size, and in their case, what was the effect size of the placebo, if you are aware of that?
Placebo effect sizes vary greatly, especially in trials for psych patients.
One of the trials had placebo panss drop of 19, very high.
The important thing to note is that as dosage of ulotaront increases, the panss score also dropped more showing that the medicine does work
This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.